DUORICH Sustained-release Tablet 5/500 mg
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Punglim Pharmaceutical Co., Ltd.
MFDS item code 202204057 · Approved 2022.11.10
Improves glycemic control in adults with type 2 diabetes mellitus
This medication helps improve blood sugar control in patients with type 2 diabetes through the combined administration of dapagliflozin and metformin. It is particularly effective when used alongside dietary management and exercise therapy. Furthermore, for patients with cardiovascular disease or risk factors, it is advisable to refer to a healthcare professional's guidance regarding potential cardiovascular events. In summary, this medication is used as an adjunct to diet and exercise to improve blood sugar levels in patients with type 2 diabetes.
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of diabetes drug therapy who have inadequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience of diabetes drug therapy, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the dose of metformin currently being taken or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this drug, the dose of this drug may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this drug have not been specifically evaluated in patients switching to it from another glucose-lowering agent. Because any change may cause a change in glycemic control, all changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This drug should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this drug may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this drug should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted by the kidneys, and renal function is more likely to be decreased in elderly patients; therefore, this drug should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medication is used for the treatment of diabetes and should not be administered to patients with impaired kidney function or certain serious diseases. It can very rarely cause a serious side effect known as lactic acidosis, so kidney function tests and symptom monitoring are necessary. Caution should be taken for the risk of hypoglycemia when used together with other diabetes medications such as insulin or sulfonylureas. This medication should be avoided in patients with acute conditions such as dehydration, severe infection, acute myocardial infarction, or sepsis, and should be discontinued for a period before and after surgery. Pregnant or nursing women should not use this medication. Elderly patients or those with weakened kidney function should frequently monitor kidney function and fluid status during the use of this medication, and dosage adjustments may be necessary. This medication may increase the risk of genital infections and urinary tract infections; therefore, any symptoms of infection should prompt immediate consultation with healthcare personnel for treatment. Vitamin B12 deficiency may occur, so checking blood vitamin B12 levels is advisable for prolonged use. Alcohol consumption can increase the risk of side effects from this medication, so excessive drinking should be avoided. If any failure in blood sugar control or abnormal symptoms occur while taking this medication, immediate consultation with a doctor is required. In case of overdose, immediate medical attention is necessary, and dialysis treatment may be required in certain cases. Dizziness or similar symptoms may occur while driving or operating machinery, so caution is needed. Keep this medication out of reach of children and store it in its original container to maintain quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering. Additionally, it is best to store it at room temperature, which ranges from 1 to 30 degrees Celsius, without extremes of heat or cold.
Orange, oval-shaped, film-coated tablets with a double convex surface
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Punglim Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.